Genmab A/S (GMAB) Stock Forecast & Price Target

Genmab A/S
Bull Case

Here are some ways that investors could benefit from investing in Genmab A/S:

• Genmab A/S recently reported strong second-quarter 2026 results, beating analyst expectations with earnings per share of $0.54 against a consensus estimate of $0.37, while also exceeding revenue forecasts with $1.16 billion in sales compared to the expected $1.12 billion, demonstrating robust commercial performance and operational efficiency.
• The stock currently trades at $33.53, which is significantly below the average analyst price target of $39.50, suggesting potential upside of nearly 18% as Wall Street maintains a consensus rating of Moderate Buy based on recent positive developments and earnings beats.
• Short interest in Genmab A/S has decreased substantially over the past several months, dropping from over 11 million shares in late 2025 to approximately 7.6 million shares by August 2026, indicating that investors are reducing bearish positions and potentially signaling increased confidence in the company's future trajectory.
• Genmab A/S has a low beta of 0.84, meaning the stock tends to be less volatile than the overall market, which can provide a more stable investment profile for investors seeking exposure to the biotechnology sector with reduced risk of sharp price swings.
• The company maintains a healthy balance sheet with a current ratio of 2.46 and a quick ratio of 2.44, indicating strong liquidity and the ability to cover short-term obligations, which supports its capacity to fund ongoing research and development initiatives for its antibody therapeutics pipeline.